Indian Pharma a Dark Horse ?

Moneycontrol analysts predict the opportunities arising of drugs off the US patent regime. Even though the BSE Healthcare has underperformed compared to sensex, these analysts are bullish on the Indian pharma industry and calls it a darkhorse.

Dr Reddy’s and Ranbaxy are well geared to take advantage of an off patent regime that has started recently. Cipla is growing through tie-ups with global pharma companies.

In the outsourcing segment we like Nicholas Piramal, Jubilant Organosys, Shasun Chemicals, and Cadila Healthcare. We are also looking at some niche stories like Marksans Pharma and Hikal Chemicals.

We like Dr Reddy’s in the short-term and Ranbaxy and GSK Pharma for the long-term as they are good value buys.